Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?
Journal of Clinical Sleep Medicine · 2023
DOI: 10.5664/jcsm.10576 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Sleep Medicine, 2023. Verfasst von François Ricordeau und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Sleep Medicine and Respiratory Diseases, Croix-Rousse Hospital, Lyon Academic Hospital, Lyon 1 University, Lyon, France. Hauptthemen laut MEDLINE: Neuropeptides, Narcolepsy, Disorders of Excessive Somnolence, Cataplexy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
According to the International Classification of Sleep Disorders, third edition guidelines, the diagnosis of narcolepsy type 1 is based on the association of excessive daytime sleepiness plus either cataplexy and electrophysiological criteria, or a cerebrospinal fluid hypocretin-1 concentration below 110 pg/mL. This threshold remains debated, and recent works have proposed alternative values in the intermediate (110 to 200 pg/mL) zone. We report the case of a patient who presented with typical clinical symptoms of narcolepsy type 1 developing over six years but in whom initial polysomnography and multiple sleep latency test were negative and cerebrospinal fluid hypocretin-1 was intermediate (132 pg/mL). Cerebrospinal fluid hypocretin-1 reassessment four years later found a dramatic decrease, < 50 pg/mL, and the multiple sleep latency test proved to be abnormal, eventually allowing to confirm the diagnosis. This case highlights the importance of reassessing patients with intermediate hypocretin-1 values and contributes to the debate on the determination of alternative cerebrospinal fluid hypocretin1 thresholds for narcolepsy type 1 diagnosis. CITATION: Ricordeau F, Bridoux A, Raverot V, Peter-Derex L. Progressive narcolepsy: how to deal with intermediate hypocretin-1 values? J Clin Sleep Med. 2023;19(7):1375-1378.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Sleep Medicine and Respiratory Diseases, Croix-Rousse Hospital, Lyon Academic Hospital, Lyon 1 University, Lyon, France.
- Service de Biochimie et biologie moléculaire, Hospices Civils de Lyon, LBMMS, F-69677 Hormonologie, Bron cedex, France.
- Neuroscience Research Center (CRNL), Inserm UMRS 1028, Université de Lyon, Waking team, Bron, France.
- Lyon Neuroscience Research Centre, CNRS UMR 5292-INSERM U1028, Bron, France.
Zitieren
APA
Ricordeau, F., Bridoux, A., Raverot, V., & Peter-Derex, L. (2023). Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.10576
Vancouver
Ricordeau F, Bridoux A, Raverot V, Peter-Derex L. Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?. Journal of Clinical Sleep Medicine. 2023. doi:10.5664/jcsm.10576
BibTeX
@article{Ricordeau2023,
author = {Ricordeau, François and Bridoux, Agathe and Raverot, Véronique and Peter-Derex, Laure},
title = {Progressive narcolepsy: how to deal with intermediate hypocretin-1 values?},
journal = {Journal of Clinical Sleep Medicine},
year = {2023},
doi = {10.5664/jcsm.10576}
}
EUVIMED